Antidepressants partially inhibit the uptake of 5-hydroxytryptamine (5-HT; serotonin) in the rat corpus callosum (CC), a white matter commissure involved in interhemispheric brain communication. It is also known that zinc modulates many proteins, including neurotransmitter transporters. We examined the effects of zinc on the uptake of 5-HT into slices of the adult rat CC, in the absence or presence of some antidepressants. Zinc increased 5-HT uptake in a concentration-dependent manner when the CC slices were incubated in a solution buffered with sodium bicarbonate; however, zinc exerted no effect on 5-HT transport when HEPES was the buffer. Potentiation of 5-HT uptake by zinc was maximal with 1 microM (45% over the control uptake). Moreover, 1 microM zinc potentiated 5-HT uptake in the cingulate cortex by 58% and in the Raphe nucleus by 65%. The antidepressants fluoxetine and imipramine inhibited 5-HT uptake in the CC by approximately 50%, whereas 6-nitroquipazine, a potent 5-HT uptake blocker, inhibited uptake by only 23%. Interestingly, inhibition of 5-HT uptake by all three substances, fluoxetine, imipramine, and 6-nitroquipazine, was counteracted by the presence of 1 microM zinc. Free zinc may thus contribute to modulation of extracellular levels of 5-HT and its removal. These actions should be considered in the treatment of mental depression with antidepressants.

2002-08-01·Bioorganic & Medicinal Chemistry3区 · 医学

Synthesis of a fluorine-18-labelled derivative of 6-nitroquipazine, as a radioligand for the In vivo serotonin transporter imaging with PET

3区 · 医学

Article

作者: Françoise Hinnen ; Frédéric Dollé ; Héric Valette ; Marcel Delaforge ; Christian Loc'h ; Laurent Besret ; Mylène Karramkam ; Yann Bramoullé ; Sébastien Bourg ; Michel Bottlaender ; Françoise Vaufrey ; Carine Franklin ; Michèle Ottaviani ; Christian Crouzel ; Christine Coulon

Considerable efforts have been engaged in the design, synthesis and pharmacological characterization of radioligands for imaging the serotonin transporter, based on its implication in several neuropsychiatric diseases, such as depression, anxiety and schizophrenia. In the 5-halo-6-nitroquipazine series, the fluoro derivative has been designed for positron emission tomography (PET). The corresponding 5-iodo-, 5-bromo- and 5-chloro N-Boc-protected quipazines as labelling precursors, as well as 5-fluoro-6-nitroquipazine as a reference compound have been synthesized. 5-[(18)F]Fluoro-6-nitroquipazine has been radiolabelled with fluorine-18 (positron-emitting isotope, 109.8 min half-life) by nucleophilic aromatic substitution from the corresponding N-Boc protected 5-bromo- and 5-chloro-precursors using K[(18)F]F-K(222) complex in DMSO by conventional heating (145 degrees C, 2 min) or microwave activation (50 W, 30-45 s), followed by removal of the protective group with TFA. Typically, 15-25 mCi (5.5-9.2 GBq) of 5-[(18)F]fluoro-6-nitroquipazine (1-2 Ci/micromol or 37-72 GBq/micromol) could be obtained in 70-80 min starting from a 550-650 mCi (20.3-24.0 GBq) aliquot of a cyclotron [(18)F]F(-) production batch (2.7-3.8% non decay-corrected yield based on the starting [(18)F]fluoride). Ex vivo studies (biodistribution in rat), as well as PET imaging (in monkey) demonstrated that 5-[(18)F]fluoro-6-nitroquipazine ([(18)F]-1d) readily crossed the blood brain barrier and accumulated in the regions rich in 5-HT transporter (frontal- and posterial cortex, striata). However, the low accumulation of the tracer in the thalamus (rat and monkey) as well as the comparable displacement of the tracer observed with both citalopram, a -HT re-uptake inhibitor and maprotiline, a norepinephrine re-uptake inhibitor (rat), indicate that 5-[(18)F]fluoro-6-nitroquipazine ([(18)F]-1d) does not have the suggested potential for PET imaging of the serotin transporter (SERT).

1999-07-01·Nuclear Medicine and Biology4区 · 医学

Characterization of bromine-76-labelled 5-bromo-6-nitroquipazine for PET studies of the serotonin transporter

4区 · 医学

Article

作者: Michele Ottaviani ; Camilla Lundkvist ; Christer Halldin ; Bernard Mazière ; Michel Bottlaender ; Chantal Fuseau ; Christian Loc’h ; Christine Coulon ; Lars Farde ; Chester Mathis

The development of suitable radioligands for brain imaging of the serotonin transporter is of great importance for the study of depression and other affective disorders. The potent and selective serotonin transporter ligand, 5-iodo-6-nitro-2-piperazinylquinoline, has been labelled with iodine-123 and used as a radioligand for single photon emission computerized tomography. To evaluate the potential of the bromine-76-labelled analogue, 5-bromo-6-nitroquipazine, as a radioligand for positron emission tomography (PET), its brain distribution and binding characteristics were examined in rats. In vivo brain distribution and ex vivo autoradiography demonstrated that [76Br]5-bromo-6-nitroquipazine enters the brain rapidly. The regional brain distribution of [76Br]5-bromo-6-nitroquipazine was consistent with the known distribution of serotonin transporters in the midbrain, pons, thalamus, striatum, and neocortex. Specific binding was inhibited by the selective serotonin reuptake inhibitor citalopram. The peripheral metabolism in plasma was rapid, but more than 90% of the radioactivity in brain represented unchanged radioligand 2 h postinjection (p.i.). A preliminary PET study was also performed in a baboon. Following the intravenous injection of [76Br]5-bromo-6-nitroquipazine in a baboon, there was a conspicuous accumulation of radioactivity in thalamus, striatum, and pons. The radioactivity in these brain regions was 1.5 times higher than in the cerebellum at 3 h and 2.5-4 times higher at 24 h. A rapid metabolism of the radioligand in plasma was observed (38% unchanged after 5 min). The results indicate that [76Br]5-bromo-6-nitroquipazine has potential for PET imaging of the serotonin transporter.

100 项与 6-nitroquipazine 相关的药物交易

登录后查看更多信息